Tiletamine
| Tiletamine | |
|---|---|
| Salts [] | |
|---|---|
| Tiletamine hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 223.34 g/mol [1] |
| Predicted LogP | 2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C12H17NOS |
| IUPAC name | 2-(ethylamino)-2-thiophen-2-ylcyclohexan-1-one |
| SMILES | CCNC1(CCCCC1=O)C2=CC=CS2 |
| InChI | InChI=1S/C12H17NOS/c1-2-13-12(11-7-5-9-15-11)8-4-3-6-10(12)14/h5,7,9,13H,2-4,6,8H2,1H3 |
| InChIKey | QAXBVGVYDCAVLV-UHFFFAOYSA-N |
| CAS number | 14176-49-9 |
| UNII | 2YFC543249 |
| PubChem CID | 26533 |
| Pharmacokinetics[] | |
|---|---|
| Metabolism | Liver |
| Excretion | Kidneys |
| Routes of administration | IV, IM, SC, Other |
Tiletamine (also known as Tiletamina, 2-(Ethylamino)-2-(2-thienyl)cyclohexanone, Cyclohexanone, 2-(ethylamino)-2-(2-thienyl)-, Tiletaminum, 2-(Ethylamino)-2-(thiophen-2-yl)cyclohexan-1-one, 238-031-9, Hsdb 7638, Prestwick0_001022, Prestwick1_001022 or Prestwick2_001022) is a n-methyl-d-aspartic acid receptor antagonist substance of the cyclohexylamine class.
Chemistry
Salts []
Stereochemistry []
Tiletamine is a racemic mixture of the enantiomers (optical activity ( + / - )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Tiletamine matches Lipinski's rule of five.Reagents
There are currently 7 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | orange | |
| Mecke | olive > slow dark blue | |
| Mandelin | no color change | |
| Liebermann | orange | |
| Froehde | no color change | |
| Morris | pale green | |
| Gallic | no color change |
Pharmacology
MeSH Classification
Mechanism of action []
Neurochemical interactions of tiletamine, a potent phencyclidine (PCP) receptor ligand, with the N-methyl-D-aspartate (NMDA)-coupled and -uncoupled PCP recognition sites were examined. Tiletamine potently displaced the binding of [3H]1-(2-thienyl)cyclohexylpiperidine with an IC50 of 79 nM without affecting sigma-, glycine, glutamate, kainate, quisqualate, or dopamine (DA) receptors. Like other PCP ligands acting via the NMDA-coupled PCP recognition sites, tiletamine decreased basal, harmaline-, and D-serine-mediated increases in cyclic GMP levels and induced stereotypy and ataxia. Tiletamine was nearly five times more potent than PCP at inhibiting the binding of 3-hydroxy[3H]PCP to its high-affinity NMDA-uncoupled PCP recognition sites. However, following parenteral administration, dizocilpine maleate (MK-801), ketamine, PCP, dexoxadrol, and 1-(2-thienyl)cyclohexylpiperidine HCl, but not tiletamine, increased rat pyriform cortical DA metabolism and/or release, a response modulated by the NMDA-uncoupled PCP recognition sites. Pretreatment with tiletamine did not attenuate the MK-801-induced increases in rat pyriform cortical DA metabolism, a result suggesting that tiletamine is not a partial agonist of the NMDA-uncoupled PCP recognition sites in this region. However, following intracerebroventricular administration (100-500 ug/rat), tiletamine increased pyriform cortical DA metabolism with a bell-shaped dose-response curve. These data indicate a differential interaction of tiletamine with the NMDA-coupled and -uncoupled PCP recognition sites. The paradoxical effects of tiletamine suggest that tiletamine might activate receptor(s) or neuronal pathways of unknown pharmacology. [1]
Interactions []
Legal status []
- Australia: Tiletamine is a Schedule 4.
- United States: Tiletamine is a Schedule III (when combined with Zolazepam) under the "Controlled Substances Act".
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 26533, Tiletamine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/26533
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Tiletamine. UNII: 2YFC543249. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2YFC543249
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 08:59:18 |
| drugspro | ok | 2026-11-20 08:59:14 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 08:59:14 |
| gsrs | ok | 2026-11-20 08:59:15 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0259091) | 2026-11-20 08:59:14 |
| kegg | ok | 2026-11-20 08:59:15 |
| pubchem | ok | 2026-11-20 08:59:11 |
| missing (no r/tripreports posts mention it) | 2026-11-20 08:59:14 | |
| sider | missing (not in SIDER) | 2026-11-20 08:59:14 |
| structure | ok | 2026-11-20 08:59:14 |
| wikipedia | ok | 2026-11-20 08:59:14 |